Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
Rhea-AI Summary
Invivyd (NASDAQ: IVVD), a biopharmaceutical company focused on protection against serious viral infectious diseases, has scheduled a conference call for Thursday, May 15, 2025, at 8:30 a.m. ET. The call will cover the company's first quarter 2025 financial results for the period ending March 31, 2025, along with recent business updates.
Analysts interested in participating in the Q&A session should join 15 minutes before the start time. The webcast will be available for replay on Invivyd's investor relations website approximately two hours after the call concludes.
Positive
- None.
Negative
- None.
News Market Reaction – IVVD
On the day this news was published, IVVD gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company’s investor relations website approximately two hours after the conclusion of the call.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
When is Invivyd (IVVD) reporting Q1 2025 earnings?
How can I listen to Invivyd's Q1 2025 earnings call?
What period will Invivyd's Q1 2025 financial results cover?
What time should analysts join Invivyd's Q1 2025 earnings call?
